Traduction de «arrive at their decisions » (Néerlandais → Français) :

It is, however, clear that although the Ethics Committees and the FAMHP arrive at their decisions independently, there is potentially a considerable amount of overlap between the interpretation of preclinical and medical aspects.
It is, however, clear that although the Ethics Committees and the FAMHP arrive at their decisions independently, there is potentially a considerable amount of overlap between the interpretation of preclinical and medical aspects.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

Furthermore an expert committee, the Committee for Advanced Therapies (CAT), was A transversal working group has been established within the FAMHP which is responsible for the coordination of this matter and the introduction of the new regulations in practice. This consultation process arrived at the following decisions:
Furthermore an expert committee, the Committee for Advanced Therapies (CAT), was A transversal working group has been established within the FAMHP which is responsible for the coordination of this matter and the introduction of the new regulations in practice. This consultation process arrived at the following decisions:

Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments.
This release contains forward-looking information that involves substantial risks and uncertainties regarding Prevenar 13, including its potential benefits; and the success of the AMC project for vaccines. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their ...[+++] class=yellow2> decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009, and in its reports on Form 10-Q and Form 8-K.

In France, 30 people die every day as a result of their own decision.
En France, trente personnes meurent chaque jour du fait de leur propre volonté.

As also discussed in notes 9 and 10 of the 2008 Annual Report, other intangible assets and investments in associated companies are reviewed for impairment whenever an event or decision occurs that raises concern about their balance sheet carrying value.
Comme le notent également les annexes 9 et 10 du Rapport annuel 2008, les autres immobilisations incorporelles et investissements dans des sociétés associées font l’objet d’un test de dépréciation dès lors qu’un événement ou une décision les concernant suscitent des doutes quant à leur valeur inscrite au bilan.

As also discussed in notes 4 and 11 of the 2009 Annual Report, investments in associated companies and intangible assets are reviewed for impairment whenever an event or decision occurs that raises concern about their balance sheet carrying value.
Comme l'indiquent également les notes 4 et 11 du Rapport annuel 2009, les investissements dans les entreprises associées et les immobilisations incorporelles font l’objet d’un test de dépréciation dès lors qu’un événement ou une décision les concernant suscitent des doutes quant à leur valeur inscrite au bilan.

In particular, as discussed in notes 4 and 11 of the 2009 Annual Report, investments in associated companies and intangible assets (including goodwill and acquired In-Process Research & Development projects) are reviewed for impairment at least annually, or whenever an event or decision occurs that raises concern about their balance sheet carrying value.
Comme l’indiquent également les notes 4 et 11 du Rapport annuel 2009, les investissements dans les entreprises associées et les immobilisations incorporelles (y compris le goodwill et les projets acquis qui sont intégrés dans le processus de recherche et développement) font l’objet d’un test de dépréciation au moins une fois par an ou dès lors qu’un événement ou une décision les concernant suscitent des doutes quant à leur valeur inscrite au bilan.

As also discussed in notes 9 and 10 of the 2008 Annual Report, intangible assets and investments in associated companies are reviewed for impairment whenever an event or decision occurs that raises concern about their balance sheet carrying value.
Comme le notent également les annexes 9 et 10 du Rapport annuel 2008, les immobilisations incorporelles et investissements dans des sociétés associées font l’objet d’un test de dépréciation dès lors qu’un événement ou une décision les concernant suscitent des doutes quant à leur valeur inscrite au bilan.